Introduction
Angiogenesis, the formation of new capillaries from pre-existing microvasculature, is a complex and crucial process during embryogenesis, female reproductive cycle, chronic inflammatory disorders, and tumor growth. 1 Many tumor masses secrete several kinds of angiogenic factors，such as vascular endothelial growth factor (VEGF), transforming growth factor-α (TGFα), and tumor necrosis factor (TNF) to promote blood vessel formation which eventually functions as a route for tumor metastasis. 2 Among these angiogenic factors, VEGF is the most prominent one, whose family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor (PIGF). They bind to three associated transmembrane tyrosine kinase receptors, known as VEGFR-1(Flt-1), VEGFR-2 (KDR or FIk-1) and VEGFR-3(FIt-3). VEGFR-2 is a key receptor for the development of the blood vasculature, 3 while VEGFR-3 is mainly involved in lymphogenesis. 4 Hence, targeting the VEGF-A/VEGFR-2 pathway has become an attractive strategy for anti-angiogenesis and tumor therapy. 2, 5 For instance bevacizumab, a very popular anti-VEGF-A antibody, has been used for the treatment of several cancers. [6] [7] [8] [9] However, it was recently reported that some patients are intrinsically refractory or acquired resistant to bevacizumab. 10 Thus development of new or adjunct therapies would be of great benefit to patients.
CD146 is a cell adhesion molecule belonging to the immunoglobulin superfamily. It was originally considered as a melanoma marker promoting melanoma growth and metastasis. 11 Recently, increasing evidence suggests that CD146 is an endothelial biomarker and promotes angiogenesis. 12, 13 CD146 knockdown impaired cardiovascular development and blocked tumor angiogenesis in zebrafish. 14 Our previous work showed that an anti-CD146
antibody, named as AA98, inhibited endothelial cell migration and angiogenesis and human tumor growth in xenografted tumor mice. 15 In
For personal use only. at Inst Biophys, CAS on June 25, 2012. bloodjournal.hematologylibrary.org From 4 addition, we found that CD146 plays an important role in cell migration that is specifically detected in invasive intermediate trophoblasts but not in non-invasive and in pre-eclampsia. 16, 17 Recently, we reported that CD146 is an epithelial-mesenchymal transition inducer and promotes the invasion of triple-negative breast cancer. 18 Although CD146 has been considered as a receptor in endothelial cells, its ligand is still unknown. 19 Our previous studies showed that tumor secretion induced CD146 dimerization, p38 MAPKs/NF-κB activation and the up-regulation of many angiogenic genes including VEGF, MMP-9 and IL-8, and that anti-CD146 mAb (AA98) interfered with this CD146-mediated signaling. 20, 21 In addition, Anfosso et al. found that CD146 associated with tyrosine kinase p59 Fyn to phosphorylate p125 Fak and paxillin, thus promoting endothelial cell migration. 22, 23 However, the molecular mechanism of how CD146 functions as a receptor in angiogenesis still remains poorly understood.
Here we show for the first time that CD146 interacts with VEGFR-2 in the endothelium, and subsequently promotes angiogenesis in vitro and in vivo.
Moreover, this CD146 and VEGFR-2 interaction and its mediated signal transduction could be blocked by anti-CD146 mAb AA98 or CD146 siRNA.
Most importantly, our animal experiments demonstrated that a combinatorial therapy with anti-CD146 AA98 and anti-VEGF (bevacizumab) has an additive killing effect on both human pancreatic carcinoma and human melanoma. Our findings not only reveal the mechanism of how CD146 plays an important role in angiogenesis, but also provide a novel insight for combinatorial therapy of tumor angiogenesis. 
Methods

Cells and animals
Human pancreatic carcinoma SW1990 cells and the human melanoma A375 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Human umbilical vein endothelial cells (HUVECs) were purchased from CellSystems (Biotechnolegie Vertrieb GmbH, Katharinen, Germany). For the generation of CD146-expressing stable human embryonic kidney cell line HEK293T clones, HEK293T cells were transfected with human PBudCE4.1-CD146 using the Fugene HD method (Roche, indianapolis, IN, USA) and selected using zeocin (500 μg/ml). HEK293T cells stably transfected with CD146 were cultured in Dulbecco's modified Eagle's medium (Gibco Life Technologies Inc., Paisley, UK) with 1 g/L glucose, 10% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. All cells were grown at 37°C and 5% CO 2 .
All animal experiments were performed in compliance with the guidelines for the care and use of laboratory animals and were approved by the Biomedical Tek +/+ CD146 floxed/floxed (named WT) mice were used as controls in Matrigel plugs assays. Genotyping of each generation was carried out using PCR. The complete absence of CD146 from the endothelial cells of vascular vessels was confirmed using immunohistochemistry and immunofluorescence.
Antibodies and reagents
Mouse anti-human CD146 mAbs, AA98 12 and AA1 24 , were made in our Human recombinant VEGF-A165 was obtained from Upstate Biotechnology.
Goat serum and DAB substrate system were from Santa Cruz Biotechnology (Santa Cruz, CA). Enhanced chemiluminescence assay kits were from Pierce (Rockford, IL, USA). Growth factor-reduced Matrigel was from BD Biosciences (Franklin Lakes, NJ, USA).
Constructs and transfection
The pCDNA3.1-(b)-CD146, pCDNA3.1-(b)-CD146/C452A, and Flag-CD146-△ KKGK has been described previously. 21, 25 The moesin construct lacking the actin-binding domain (MSN-△ABD) was generated by a polymerase chain reaction-based approach using Flag-MSN as a template. Fugene HD mediated transfection was employed according to the manufacture's instruction. 21 For siRNA transfections, HUVECs were transfected with 50 nM of either GFP siRNA or CD146 siRNA, using the Fugene HD method. Cells were then incubated for 36 h at 37°C and 5% CO 2 .
RNA interference
In vitro pull-down assays 0.15 μg Fc or Fc-sVEGFR-2 was conjugated to protein G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA). The beads were then incubated with 0.15 μg His-sCD146 protein for 1 h at 4°C. Proteins bound to the beads were then boiled in sample loading buffer and subjected to immunoblotting analysis.
Co-immunoprecipitation
HUVECs were lysed in a culture dish by adding 0.5 ml ice-cold RIPA lysis buffer for 30 min. The supernatants were collected by centrifugation at 12,000 g for 10 min at 4°C and then precleared with protein G-Sepharose to remove the protein G-bound proteins. The cleared lysates were then incubated with antibodies at 4°C overnight, followed by incubation with protein G-Sepharose for 4 h. Immunoprecipitates were washed three times with lysis buffer and then boiled for 5 min in loading buffer.
Activation of RTKs and downstream signals
Serum-starved HUVECs (24 h) were incubated with blocking reagents (50 μg/ml mAbs AA98 or AA1) or transfected with siRNA (CD146-siRNA or GFP-siRNA) prior to induction with VEGF-A165 (50 ng/ml) at 37°C for 10 min, 30 min, or 12 h for analysis of the activation of VEGFR-2, p38/AKT/Erk, and NF-κB, respectively. Cells were washed with ice-cold PBS, lysed in RIPA lysis buffer and then subjected to Western blotting as described. Blots were probed separately with anti-phosphorylated antibodies against VEGFR-2, Erk, p38, 
Immunofluorescence
Cells were plated on slides cultured in six-well plates and then subjected to appropriate treatments. After stimulation for 24 h with VEGF-A165 (50 ng/ml), the cells were washed with PBS, fixed in acetone:methanol (1:1) for 30 s, permeabilized with 0.1% Triton X-100, blocked with 5% normal goat serum for 60 min at 37°C, and then incubated with anti-p65 or anti-p50 for I h. Coverslips were subsequently examined with a confocal laser scanning microscope (Olympus, Tokyo, Japan).
Tube formation
The tube formation assay was performed as described by Nagata et al. 26 Tube formation was observed under an inverted microscope (Eclipse Model TS100;
Nikon, Japan). Images were captured with a CCD color camera (Model KP-D20AU; Hitachi, Japan) attached to the microscope and tube length was measured using NIH ImageJ software.
Cell migration assay
Cell migration was assayed using a modified Boyden chamber assay as described (8-μm pore size; Costar, Corning, NY). 27 After the appropriate treatments, cells were trypsinized, washed, and resuspended in fresh serum-free medium (10,000 cells per well). After incubation at 37°C overnight, cells remaining at the upper surface of the membrane were removed using a swab, while cells that migrated to the lower membrane surface, representation of migrated cells, were fixed with 4% PFA and stained with Giemsa solution.
The number of cells migrating through the filter was counted and plotted as the number of migrating cells per optic field (20X).
Immunohistochemistry
For personal use only. at Inst Biophys, CAS on June 25, 2012. bloodjournal.hematologylibrary.org From 9 For 3,3'-Diaminobenzidine (DAB) staining, paraffin-embedded tissue sections were deparaffinized and stained first with an antibody specific for CD31, and then with biotin-conjugated secondary antibodies (1:1000), followed by HRP-conjugated streptavidin (Dianova, Rodeo, CA). The sections were finally counterstained with hematoxylin. The number of blood vessel per tumor in each group was quantified in at least 10 random areas per section. Images were taken using an inverted microscope (Eclipse Model TS100; Nikon, Japan).
For immunohistofluorescence, sections 5 μm in thickness were deparaffinized and stained with antibodies specific for CD31 and CD146, followed by fluorescent-labeled secondary antibodies. Nuclei were stained with DAPI.
In vivo angiogenesis assay
Age-and sex-matched CD146 EC-KO mice and wild-type mice were used. Mice 
Results
CD146 interacts with VEGFR-2 in endothelial cells
The co-expression of CD146 and VEGFR-2 on endothelial cells and the finding that tumor secretions containing VEGF and FGF induced CD146-mediated p38 MAPKs/NF-κB signaling led us to hypothesize that CD146 may act as a co-receptor for VEGFR-2. To test this, we performed co-immunoprecipitation Figure 1B ). In addition, we also found that CD146 did not interact with VEGFR-1 ( Figure S7 ).
To further investigate whether or not CD146 directly interacts with VEGFR-2, we carried out in vitro pull down assays using soluble CD146 (His-tagged CD146 extracellular domain, His-sCD146) and soluble VEGFR-2 (Fc-tagged VEGFR-2 extracellular domain, Fc-sVEGFR-2). Results showed that Fc-sVEGFR-2 was specifically bound to His-tagged CD146 as it bound to VEGF. In contrast, neither Fc nor Fc-beads were bound by His-sCD146 ( Figure 1C ). These data demonstrate a direct interaction between the CD146 extracellular domain and VEGFR-2.
Next, we ascertained whether the interaction of CD146 and VEGFR-2 could be abrogated by anti-CD146 antibody. To test a possible structural basis of CD146 binding to VEGFR-2, we used two different anti-CD146 antibodies, AA98 and AA1. AA98 recognizes a conformational epitope at C452-C499, For personal use only. at Inst Biophys, CAS on June 25, 2012. bloodjournal.hematologylibrary.org From whereas AA1 recognizes a linear epitope at aa50-54 in the N-terminal domain. 21 Figure 1D showed that the interaction between CD146 and VEGFR-2 was markedly blocked by AA98 but not by AA1. To confirm this observation, we performed the Co-IP experiment in HUVECs using CD146/C452A mutant and found that the endogenous interaction of CD146
and VEGFR-2 was abrogated by the CD146/C452A mutation ( Figure 1E ), suggesting that C452 in domain five of CD146 contributes to the interaction of CD146 and VEGFR-2. This may explain why the anti-CD146 antibody, AA98
but not AA1 inhibited this interaction.
CD146 enhances VEGFR-2 phosphorylation and downstream signaling
As CD146 associated with VEGFR-2, we next asked whether CD146
transduces VEGF-activation signals. For this purpose, we used VEGF as a stimulator, and anti-CD146 AA98 and CD146 siRNA as inhibitors to evaluate the function of CD146 on VEGF-induced signaling pathway. As shown in 
3A-D)
. In addition, nuclear translocation of NF-κB p65 and p50 induced by VEGF was also inhibited by CD146-siRNA and re-activated by restoring CD146 expression ( Figure 3E ). In contrast, VEGF-induced Erk signaling was not affected by either AA98 or CD146-siRNA ( Figure S2 ), implying that CD146 was mainly involved in the VEGF-induced Akt and p38/IKK/NF-κB pathways.
To test whether CD146 function is specifically dependent on VEGF, we repeated the experiments with TNFα, another angiogenic factor. We found that neither AA98 nor CD146 siRNA had any effects on the response of NF-κB to TNFα stimulation ( Figure S3) , suggesting that the response of CD146 to VEGF is specific.
Taken together, these data strongly suggest that CD146, as a VEGFR-2 co-receptor, is involved in regulating VEGF-induced VEGFR-2 downstream signals.
CD146 mediated ERM recruitment is essential for VEGF-mediated signal transduction and cell migration
We previously reported that CD146 interacted physically with ERM proteins (Ezrin-Radixin-Moesin) leading to the subsequent promotion of cell migration.
The conserved positively-charged amino-acid cluster KKGK motif is responsible for the interaction of CD146 and ERM in this process. 25 It has been shown that some co-receptors such as CD44, interacts with ERM proteins and the cytoskeleton to promote signaling efficiently. CD44v6, VEGFR-2/c-Met, ERMs and the cytoskeleton form a signalosome. 25, 28 To evaluate whether this mechanism is also essential for VEGFR-2 signaling, we transfected HUVECs with a CD146 construct lacking the KKGK motif (CD146-△ KKGK) or a moesin construct lacking the actin-binding domain (MSN-△ABD).
As shown in Figure 4A -B, we found that either CD146-△KKGK or MSN-△ABD disturbed VEGF-induced VEGFR-2 downstream signaling without affecting These data suggest that the interaction of CD146 and ERM is essential for VEGF-induced signal transduction and cell migration.
CD146 is required in cell migration and tube formation induced by VEGF
To investigate the function of CD146 in the VEGF-promoted angiogenesis process, we performed endothelial cell migration and tube formation assays in the presence of AA98 and AA1. First, we tested the role of CD146 in VEGF-induced endothelial cell migration. As shown in Figure 5A , VEGF-induced motility of HUVECs was strongly suppressed by AA98, but not by AA1.
In addition, VEGF-stimulated cell migration was significantly impaired after CD146 knockdown in HUVECs, and rescued after transfection with a CD146-expressing construct. Quantification of the number of migrated cells revealed a 1.5-fold increase in VEGF-stimulate HUVEC migration which was abrogated by CD146-siRNA treatment ( Figure 5C ).
Next, we examined the function of CD146 on in vitro angiogenesis induced by VEGF. A tube formation assay was performed by growing endothelial cells in matrigel with either anti-CD146 antibody AA98 or AA1. Results showed that VEGF promoted endothelial tubular morphogenesis and accelerated tube formation. However, in the presence of AA98, the length of vessels decreased by 50% compared with that in the presence of AA1 ( Figure 5B ). This VEGF-promoted tube formation was also found to be markedly suppressed when CD146 was knocked-down in HUVECs by transfecting with CD146-siRNA. Tubular morphogenesis could be rescued by restoring CD146 levels ( Figure 5D ).
For personal use only. at Inst Biophys, CAS on June 25, 2012. bloodjournal.hematologylibrary.org From Moreover, we found that the CD146 mediated-tube formation is specifically dependent on VEGF, because when TNFα was used as a stimulator, neither CD146 knockdown nor anti-CD146 AA98 affected the angiogenic process ( Figure S4 ). This may also help explain the more profound effect of AA98 on angiogenesis in vitro than in vivo.
VEGF-induced angiogenesis is impaired in CD146 EC-KO mice
To explore the potential role of CD146 in VEGF-mediated angiogenesis in vivo, we used a matrigel plug model in which matrigel mixed with VEGF is injected subcutaneously into age-and sex-matched CD146 EC-KO and wild type mice. In this system, endothelial cells migrate into the matrigel and form a capillary network. One week post-implantation, the numbers of blood vessels are counted by immunofluorescence using the blood vessel marker, CD31. Our results showed that the microvascular density of the matrigel plugs in CD146 EC-KO mice decreased to 47% when compared to that of the wild-type mice and no large vascular tubes were seen ( Figure 6 ), indicating that the VEGF-induced angiogenic response is dependent on CD146 in vivo.
AA98 and Bevacizumab cumulatively inhibit human pancreatic carcinoma growth
It has been well documented that tumor growth is dependent on angiogenesis, and both AA98 and bevacizumab have previously been reported to inhibit tumor angiogenesis. 12, 29, 30 Our finding that CD146 acts as a co-receptor for VEGFR-2 prompted us to determine whether AA98 and bevacizumab could produce an additive effect on inhibiting tumor growth. We developed a tumor model using the human pancreatic carcinoma cells, SW1990, that express neither CD146 nor VEGFR-2 ( Figure S5 ). Thus neither AA98 nor bevacizumab In immunohistochemical analysis of the treated tumors, we observed a significant reduction of microvessel density in both AA98 and bevacizumab treated groups. However, in the AA98+bevacizumab combination treated group, the vessel numbers were approximately 40% and 30% less than that of AA98 or bevacizumab treatment alone ( Figure 7D ).
In addition, we also found this additive effect of AA98 and bevacizumab on another tumor model: human melanoma xenografted mice with A375 cells ( Figure S6 ).
These data suggest that the combination of AA98 with bevacizumab to target tumor angiogenesis could eventually be used in a clinical setting. 
Discussion
There is increasing evidence supporting a role for CD146 in angiogenesis. 12, 15 We hypothesized that a possible link between CD146 and VEGFR-2 existed as both are endothelial markers and involved in Akt and p38 MAPK downstream signaling to promote endothelial cell migration and angiogenesis.
However, there has been no direct evidence demonstrating the relationship between CD146 and VEGFR-2. In this study, we show for the first time that Although several VEGFR-2 co-receptors, [31] [32] [33] [34] [35] including Neuropilin-1, 36 For personal use only. at Inst Biophys, CAS on June 25, 2012. bloodjournal.hematologylibrary.org From Neuropilin-2 37 and CD44v6, 28 have been reported to play a role in VEGFR-2 signaling and angiogenesis, we found that unlike Neuropilin-1 and Neuropilin-2, whose interactions with VEGFR-2 are dependent on VEGF treatment, and mainly involved in the VEGFR-2-Erk pathway which eventually results in cell proliferation, the interaction of CD146 with VEGFR-2 is independent of VEGF treatment (data not shown), and is involved in the VEGF-mediated p38 MAPKs and AKT signaling pathway which culminates in cell migration. These observations suggest that the different VEGFR-2 co-receptors may trigger different downstream signals resulting in different cell functions. Thus, it is of particular interest to elucidate the relationship of these co-receptors, such as CD146, CD44v6 or Neuropilin-2, in VEGF-mediated angiogenesis.
There also exists common mechanism for VEGFR-2 co-receptors signaling.
Both the cytoplasmic tail of CD146 and CD44 recruits ERM proteins and cytoskeleton for VEGF-induced signal transduction, suggesting that a scaffold is necessary for linking the intracellular signaling molecules together at the docking site of VEGFR-2. In addition, as is the case for PDGFRs, which have no known co-receptor, ERMs are needed for signal transduction. 38 Binding of ERM proteins to the cytoskeleton may thus be a common mechanism essential for signal transduction.
Based on all the above observations, we conclude that the regulation of CD146 as a VEGFR-2 co-receptor in the VEGF signaling pathway and angiogenesis by two-pronged: firstly, the extracellular domain of CD146 directly interacts with VEGFR-2, forms a complex with VEGFR-2 and VEGF which is a crucial step for VEGFR-2 activation. Secondly, the cytoplasmic tail of CD146 recruits ERMs and cytoskeleton, assembling the signalsome required for signal transduction from VEGFR-2 to AKT and p38 MAPKs.
In the SW1990 tumor model, we made use of bevacizumab, an anti-VEGF antibody as a combination partner for AA98. We believe that bevacizumab mediated its anti-tumor effect primarily through the blocking of Interestingly, AA98 and bevacizumab combination therapy showed additive effect on tumor angiogenesis in the SW1990 tumor model, which is in agreement with another study showing synergistic, pro-angiogenic effects between soluble CD146 and VEGF. 41 Therefore, the synergistic effect between the combined antibodies is due to the incomplete overlapping signaling of CD146 and VEGFR-2. In previous reports, we and others have found that CD146 can also function independently of VEGFR-2. C: Cells co-transfected with CD146-siRNA and pcDNA3.1-CD146 were subjected to "Cell migration assays" as described. The number of cells migrating through the filters was recorded.
The number of cells per optic field is presented as the mean ± SEM of at least three independent assays. D: Cells co-transfected with CD146-siRNA and pcDNA3.1-CD146 were subjected to "Tube formation assays" as described. Results presented are total tube lengths from three independent tests (means ± SEM). *P<.05, ** P<.01, *** P<.001, NS.: not significant. 
